Regulatory
2020 Democratic Presidential Run
By Pete Evich, AAHP Government Relations As the 2020 U.S. presidential election inches closer, many Democratic hopefuls have launched campaigns to take the White House. At AAHP, we are keeping a close eye on the candidates and proposed policies that could affect the homeopathic industry. Here is an overview readm more…
Read MoreSummit Photos: Experience the Excitement
The AAHP community is still abuzz from all the excitement, networking, and learning that took place at last month’s Quality and Safety Summit in Baltimore! Between the opening reception and following day of sessions, we hosted more than 100 people from five countries across the globe. With a keynote session readm more…
Read MoreEducational Webinar Resources Available
Missed an education opportunity? Need materials for your mandated employee training? You have a second chance! AAHP webinars can help fulfill your required mandatory staff training requirements. Homeopathic manufacturers and marketers have found AAHP to be an excellent third-party source for this training. All DVD’s include an MP4 recording readm more…
Read MoreA First Look at AAHP Summit Speakers
We are thrilled to offer a first look at the speakers and sessions for our upcoming Summit on Challenges and Solutions in Quality & Safety of Homeopathic Drug Products! This unique one-day workshop is designed to help you manufacture safe products while complying within FDA and FTC guidelines. Some of readm more…
Read MoreHow to Work with FDA on Voluntary Recalls
By Mary Borneman, Sr. Director, Communications & Public Affairs, Standard Homeopathic Company/Hyland’s, Inc. In April 2019, U.S. Food & Drug Administration (FDA) published a draft guidance* Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C (“the Draft Guidance”). The purpose of this new guidance is “to clarify readm more…
Read MoreInitiation of Voluntary Recalls: Draft Guidance for Industry and FDA Staff
By Mark Land, AAHP President Product recalls are an important tool that manufacturers and the U.S. Food and Drug Administration (FDA) use to minimize exposure to potentially harmful or ineffective products.1 Drug product recalls are voluntary — that is to say, FDA does not have legal authority to recall readm more…
Read MoreOverview: Membership Meeting 2019
The membership of AAHP came together on March 8 for the association’s semiannual Membership Meeting. Taking place during Natural Products Expo West in Anaheim, Calif., AAHP members convened to hear updates on projects and initiatives, network, and elect new leadership before hitting the tradeshow floor. Three-Pronged Strategic Approach for 2019 readm more…
Read MoreReduce Risk with Product Substantiation
Susan J. Hewling When bringing products to market, it is essential to build a platform that allows all information generated to be available for future use,” advised Susan J. Hewlings, PhD, RD, during a preview for her workshop this June at the AAHP Summit in Baltimore. Guest speaker at readm more…
Read MoreNew Congress, New Landscape: What it Means for the Homeopathic Industry
By Pete Evich, AAHP Government Relations Shutdown Impacts FDA The 116th Congress commenced on Jan. 3 amidst a turbulent backdrop of a partial federal government shutdown. On Jan. 25, after a record-breaking 35-day shutdown, President Trump agreed to sign legislation to fund the impacted federal government agencies until Feb. 15. readm more…
Read MoreOutlook 2019: A Letter from the Board
By AAHP Board of Directors 2019 presents a unique crossroad to the homeopathic industry. As consumer demand for our products rises across North America, so does industry growth—and it is poised to continue growing. With this increased visibility comes increased scrutiny from regulatory bodies and potentially unfriendly consumer groups. While readm more…
Read More